C R Bard (BCR) Receives Media Sentiment Score of 0.21

Media headlines about C R Bard (NYSE:BCR) have trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. C R Bard earned a news impact score of 0.21 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 45.2142487039528 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

C R Bard has a 12 month low of $223.02 and a 12 month high of $337.73. The company has a market cap of $24,140.00, a P/E ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

Several research analysts have recently issued reports on BCR shares. Zacks Investment Research upgraded shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price objective for the company in a report on Tuesday, December 26th. Cowen reiterated a “hold” rating and issued a $317.00 price objective on shares of C R Bard in a report on Friday, November 3rd. ValuEngine lowered shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Finally, Barclays increased their target price on shares of C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research note on Monday, November 6th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the stock. C R Bard has an average rating of “Hold” and an average price target of $320.83.

In related news, insider Jim C. Beasley sold 3,395 shares of the company’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $332.00, for a total value of $1,127,140.00. Following the completion of the sale, the insider now owns 25,630 shares in the company, valued at approximately $8,509,160. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP John A. Deford sold 14,107 shares of the company’s stock in a transaction that occurred on Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The disclosure for this sale can be found here. Over the last three months, insiders have sold 32,546 shares of company stock valued at $10,826,150. Company insiders own 0.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by Markets Daily and is owned by of Markets Daily. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2018/02/26/c-r-bard-bcr-receives-media-sentiment-score-of-0-21.html.

C R Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply